Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Change in Account Payables came in at $4.2 million in Q1 2026, up 4.63% YoY from $4.1 million in Q1 2025, and up 350.29% on a QoQ basis from -$1.7 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Change in Account Payables data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Change in Account Payables rose 4.63% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119000.0 (up 111.02% YoY) and the FY2025 annual result came in at -$69000.0, up 99.28% from the prior year.
- Change in Account Payables climbed to $4.2 million in Q1 2026, from -$1.7 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.9 million in Q1 2023 to a low of -$5.2 million in Q4 2024.
- A 5-year average of -$164176.5 and a median of $80000.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 456.57% in 2024, down 2090.0% in 2024.
- Tracing XERS's Change in Account Payables over 5 years: stood at $690000.0 in 2022, then plunged by 151.16% to -$353000.0 in 2023, then tumbled by 1373.94% to -$5.2 million in 2024, then soared by 67.36% to -$1.7 million in 2025, then surged by 350.29% to $4.2 million in 2026.
- The last three Change in Account Payables figures came in at $4.2 million (Q1 2026), -$1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 286,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 286,000.00 |
| Jun 30, 2026 | 286,000.00 |
| Mar 31, 2026 | 4.25 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Dec 31, 2025 | -1.70 Mn |
| Dec 31, 2025 | -1.70 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -4.43 Mn |
| Jun 30, 2025 | -4.43 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Dec 31, 2024 | -5.20 Mn |
| Dec 31, 2024 | -5.20 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Mar 31, 2024 | -4.47 Mn |